Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.
Amivantamab vs Alternative Therapies in Patients with EGFR Exon 20–Mutated NSCLC
Discussing Post Hoc Analyses from the REACH2 Trial
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
ASCENT: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Sacituzumab Govitecan in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Between The Lines: Once Weekly Selinexor, Carfilzomib & Dexamethasone in Carfilzomib Non-Refractory Multiple Myeloma Patients
Between The Lines: Guidelines for Use and Dosing of Selinexor in Multiple Myeloma
Tazemetostat in Relapsed/Refractory Follicular Lymphoma: A Propensity Score–Matched Analysis of E7438-G000-101 Trial Outcomes
CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions
US Physician Paradigm Study Informs Decision-Making in Locally Advanced/Metastatic Urothelial Carcinoma
Between The Lines: Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Utility of ctDNA to Manage Adjuvant Therapy in CRC Based on Results of the GALAXY Study
Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma
Reviewing Data on Lenvatinib plus Pembrolizumab Combination Treatment for Advanced Renal Cell Carcinoma
Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC
Routine Clinical Practice Comparison of IRD and Rd in RR Multiple Myeloma
The Role of Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer
Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia
Clinical Practice Experience with Avelumab First-Line Maintenance in Urothelial Carcinoma
18F-Fluciclovine Versus 68Ga-PSMA-11 Imaging for Prostate Cancer Biochemical Recurrence
Immune Checkpoint Inhibitors as Switch or Continuous Maintenance Therapy in Solid Tumors: Rationale and Current State
Incorporating Real-World Evidence into Clinical Decisions in NSCLC
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers
Circulating Tumor DNA as a Biomarker of Progression in Colorectal Cancer
PET/CT–Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer
Personalized Circulating Tumor DNA Analysis as a Predictive Biomarker in Solid Tumors
Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions
Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to A Pandora’s Box